bioRxivCancer Biology
Molecular Determinants of Calcitriol Signaling and Sensitivity in Glioma Stem-like Cells
S. Rehbein, A.-L. Possmayer, S. Bozkurt, C. Lotsch, J. Gerstmeier, M. Burger, S. Momma, C. Maletzki, C.-F. Classen, T. M. Freiman, D. Dubinski, K. Lamszus, B. W. Day, B. W. Stringer, C. Herold-Mende, C. Münch, D. Kögel, B. Linder
Abstract
Glioblastoma is the most common primary brain cancer in adults and represents one of the worst cancer diagnosis for the patients. Suffering from a poor prognosis and limited treatment options, tumor recurrences are virtually inevitable. Additionally, treatment resistance is very common for this disease and worsens the prognosis. These and others factors are hypothesized to be largely due to the fact that glioblastoma cells are known to be able to obtain stem-like traits and thereby driving these phenotypes. Recently, we could show that the in vitro and ex vivo treatment of glioblastoma stem-like cells with the hormonally active form of Vitamin D3, Calcitriol (1,25(OH)2-vitamin D3) can block stemness in a subset of cell lines and reduce tumor growth. Here, we expanded our cell panel to over 40 different cultures and can show that, while half of the tested cell lines are sensitive, a quarter can be classified as high-responders. Using genetic and proteomic analysis, we further determined that treatment success can be partially explained by specific polymorphism of the Vitamin D3 receptor and that high-responders display a proteome suggestive of blockade of stemness, as well as migratory potential.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The functional genomic circuitry of human glioblastoma stem cells
Graham MacLeod, Danielle A. Bozek, … Stephane Angers·bioRxiv·Jun 28, 2018
- Targeting glucocorticoid signalling in dendritic cells for glioblastoma treatment
Qiuchen Zhao, Jhuma Pramanik, … Bidesh Mahata·bioRxiv·Aug 12, 2026
- Chi3l1 is a modulator of glioma stem cell states and a therapeutic vulnerability for glioblastoma
C. Guetta-Terrier, D. Karambizi, … N. Tapinos·bioRxiv·Oct 1, 2021
- Pharmacological induction of mitochondrial stress counteracts therapy resistance in glioblastoma stem-like cells
Kenji Miki, Maged T Ghoche, … Kalil G. Abdullah·bioRxiv·Feb 9, 2026
- Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and Chemoradiation
Yu Pu Yang, Austin Arrigo, … Hui‐Wen Lo·bioRxiv·Feb 20, 2025
- Impact of genomic background and developmental state on signaling pathways and response to therapy in Glioblastoma patient-derived cells
A. D. Berezovsky, O. Nuga, … A. deCarvalho·bioRxiv·Mar 14, 2024